Role of other lncRNAs in CVDs is demonstrated by lncRNA MIAT, which is associated with increased risk of myocardial infarction [56]; lncRNA ANRIL is associated with increased risk to coronary heart disease [57]; lncRNA DBE-T localizes to the facioscapulohumeral muscular dystrophy (FSHD) locus [58]; and a novel lncRNA is identified in association with HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets) [59]. Here, CDKN2B-AS1 is linked to facioscapulohumeral muscular dystrophy.